Acinlcal trial reports that patients taking a new drug, NO-G0, experience less incontinence eplsodes. The number of incontinent eplsodes (the primary endpolnt) was 16.4% in the NO.GO group and 28.7% In the placebo group. The trial randomized 600 patients (300 patients in each am) What ls the absolute risk reduction of the primary endpolnt
[Answered]: Acinlcal trial reports that patients taking a new…
Need help with your Clinical Case Studies case study or NCLEX preparation? Connect with a verified Nursing expert now.